Benzinga | Feb 2, 2021 07:15AM EST

Kodiak Sciences Highlights Presentation Of KSI-301 Phase 1b Trial Study Data At Angiogenesis, Exudation, Degeneration On Feb. 13, 2021 At 8:30 a.m. EST

Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 -- Virtual Edition meeting.

Details of the presentation are as follows:

Title: KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases

Presenter: Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine, Stanford, CA

Presentation date and time: February 13, 2021; 8:30 AM ET

"We look forward to presenting one-year data from our Phase 1b study of KSI-301 in patients with wet AMD, DME and RVO at Angiogenesis," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 1b data presented to date demonstrate excellent safety, strong efficacy and remarkable durability in these treatment-na?ve patient cohorts. With two in every three patients achieving a six month or longer treatment-free interval at year one after only three loading doses, we continue to believe KSI-301 has the potential to meaningfully improve the care for all patients with retinal vascular diseases."

Kodiak plans to issue a press release relating to the data and post the slide presentation on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of Dr. Do's presentation.